We are live on
!
Find out more
Lazard Asset Management Portfolio holdings
AUM
$60.8B
1-Year Est. Return
22.47%
This Fund
S&P 500
This Quarter
Est. Return
+5.89%
1 Year Est. Return
+22.47%
3 Year Est. Return
+62.53%
5 Year Est. Return
+77.87%
10 Year Est. Return
+302.07%
AUM
$47.8B
AUM Growth
+$3.07B
(+6.9%)
Cap. Flow
-$507M
Cap. Flow
% of AUM
-1.06%
Top 10 Holdings %
Top 10 Hldgs %
17.74%
Holding
1,131
New
130
Increased
292
Reduced
306
Closed
143
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teva Pharmaceuticals
TEVA
|
+$526M |
| 2 |
Ally Financial
ALLY
|
+$198M |
| 3 |
CSX Corp
CSX
|
+$191M |
| 4 |
NetEase
NTES
|
+$173M |
| 5 |
Norwegian Cruise Line
NCLH
|
+$171M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$262M |
| 2 |
CVS Health
CVS
|
+$240M |
| 3 |
Mastercard
MA
|
+$204M |
| 4 |
McKesson
MCK
|
+$201M |
| 5 |
Molson Coors Class B
TAP
|
+$171M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 14.83% |
| 2 | Communication Services | 13.94% |
| 3 | Technology | 12.15% |
| 4 | Financials | 10.5% |
| 5 | Energy | 9.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
226
Enerpac Tool Group
EPAC
$1.9B
| $24.8M | 0.05% |
717,638
+86,710
| +14% | +$3.01M |
|
|
GDL
227
GDL Fund
GDL
$91.7M
| $24.5M | 0.05% |
2,252,155
-523,379
| -19% | -$5.75M |
|
228
State Street Technology Select Sector SPDR ETF
XLK
$112B
| $24.4M | 0.05% |
1,273,060
-128,000
| -9% | -$2.37M |
|
229
Kroger
KR
$36.3B
| $24.2M | 0.05% |
977,330
-10,156
| -1% | -$237K |
|
230
Vanguard FTSE Emerging Markets ETF
VWO
$119B
| $24.1M | 0.05% |
559,325
+545,176
| +3,853% | +$23M |
|
231
TriMas Corp
TRS
$1.44B
| $23.4M | 0.05% |
771,096
+30,012
| +4% | +$836K |
|
232
PNC Financial Services
PNC
$100B
| $23.2M | 0.05% |
261,003
-16,730
| -6% | -$1.43M |
|
233
United Bankshares
UBSI
$6.71B
| $23.2M | 0.05% |
716,165
+145,839
| +26% | +$4.44M |
|
|
DO
234
DELISTED
Diamond Offshore Drilling
DO
| $22.3M | 0.05% |
448,856
+198,869
| +80% | +$9.9M |
|
235
MetLife
MET
$62.7B
| $22.2M | 0.05% |
447,978
+15,317
| +4% | +$717K |
|
236
iShares MSCI Emerging Markets ETF
EEM
$28B
| $21.9M | 0.05% |
506,191
+437,369
| +636% | +$18.6M |
|
|
IFN
237
Aberdeen India Fund
IFN
$496M
| $21.7M | 0.05% |
853,349
-448,249
| -34% | -$10.6M |
|
238
Mohawk Industries
MHK
$7.14B
| $21.6M | 0.05% |
+156,438
| New | +$21.1M |
|
239
Phibro Animal Health
PAHC
$1.48B
| $21.4M | 0.04% |
+976,505
| New | +$18.6M |
|
240
State Street SPDR Portfolio Short Term Corporate Bond ETF
SPSB
$10.4B
| – | – |
0
| – | – |
|
|
HAWK
241
DELISTED
Blackhawk Network Holdings, Inc. Common Stock
HAWK
| $21.2M | 0.04% |
751,761
-81,232
| -10% | -$2.02M |
|
|
ALU
242
DELISTED
Alcatel-Lucent
ALU
| $21.2M | 0.04% |
5,955,354
+34,210
| +0.6% | +$132K |
|
243
LyondellBasell Industries
LYB
$18.8B
| $21.1M | 0.04% |
215,725
+66,134
| +44% | +$6.3M |
|
244
Ameriprise Financial
AMP
$48.3B
| $21.1M | 0.04% |
175,491
+2,185
| +1% | +$244K |
|
245
American International
AIG
$42.9B
| $20.9M | 0.04% |
383,191
+16,556
| +5% | +$877K |
|
246
Walt Disney
DIS
$172B
| $20.9M | 0.04% |
243,258
+49,837
| +26% | +$4.07M |
|
|
FEO
247
DELISTED
First Trust/abrdn Emerging Opportunity Fund
FEO
| $20.8M | 0.04% |
1,087,196
-64,618
| -6% | -$1.21M |
|
|
JFC
248
DELISTED
JPMorgan China Region Fund, Inc.
JFC
| $20.8M | 0.04% |
1,363,504
-10,300
| -0.7% | -$149K |
|
249
Steven Madden
SHOO
$3.22B
| $20.7M | 0.04% |
903,299
+119,693
| +15% | +$2.69M |
|
250
Expro Ltd
XPRO
$1.75B
| $20.2M | 0.04% |
136,933
-92,926
| -40% | -$13.7M |
|
Similar funds
QCM
Lazard Asset Management's Q2 2014 Portfolio in Review
As of Q2 2014, Lazard Asset Management held 1,131 positions worth $47.8B, up 6.9% from $44.8B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Lazard Asset Management's Q2 2014 filing shows 130 new, 292 increased, 306 reduced and 143 closed positions. Its largest new stake was Ally Financial: 8,153,883 shares worth $195M. The largest sale was Gilead Sciences, an estimated $262M.
By sector, the portfolio is most concentrated in Healthcare at 15% of assets, down from 16% a quarter earlier, followed by Communication Services and Technology.
- Lazard Asset Management's largest Q2 2014 buy was Ally Financial: 8,153,883 shares worth $195M.
- Lazard Asset Management added most to Teva Pharmaceuticals in Q2 2014, an estimated $526M increase.
- Lazard Asset Management's biggest Q2 2014 reduction was Gilead Sciences, cutting an estimated $262M.
- Lazard Asset Management fully exited Mastercard in Q2 2014, selling an estimated $204M.
- Lazard Asset Management's ten largest holdings make up 18% of its $47.8B portfolio in Q2 2014.
- Lazard Asset Management opened 130 new positions and closed 143 in Q2 2014.
- Lazard Asset Management's portfolio value rose 6.9% quarter-over-quarter to $47.8B.
Based on Lazard Asset Management's 13F filing for Q2 2014, filed 12 Aug 2014.